Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients

Withdrawn before enrolling

Conditions studied: Metastatic Breast Cancer, Breast Cancer

In brief

The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States. The objective of the present registry is to demonstrate the impact on patient management of the CELLSEARCH® CTC Test among the Medicare-eligible mBC patients. Hereto the hypothesis that the availability of CTC information provides clinicians important, timely information and impacts treatment decisions, will be tested. This study is IDE-exempt since CELLSEARCH® CTC Test is a legally marketed device in the US, and is being used in accordance with its labeling.

Key facts

Study ID

NCT02111031

Run by

Janssen Diagnostics, LLC

People needed

0

Starts

2016-01-01

Expected to finish

2017-05-01

Last updated by the study team

2015-06-19

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has documented (histologically/pathologically confirmed) mBC diagnosis
• Patient is at least 65 years of age at time of mBC diagnosis
• Patient is male or female
• Patient is being actively treated at the cancer center by a physician who uses or plans to use CTC testing on his mBC patients at lease every quarter.

You may not qualify if…

• Patients breast cancer is secondary not primary

Where it is running

• Abramson Cancer Center, University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.